

Share Price (Apr 20)	US\$4.00
Basic Shares Out	7.2M
Basic Market Cap	US\$29M



William V. Williams, MD, FACP
President & CEO, Director

- Former VP, Exploratory Development, Incyte
- Former VP, Experimental Medicine, GlaxoSmithKline
- 11 drug approvals




Jamieson Bondarenko, CFA, CMT
Chairman of the Board

- Former Managing Director, Equity Capital Markets, Eight Capital
- Former Managing Director, Dundee Securities Ltd.

WHO ARE WE?

- A clinical stage immunotherapy company driven to fight cancer and improve patients' lives
- Lead asset Bria-IMT™ boosts the ability of the body's own cancer-fighting cells to destroy cancer
- Ongoing pivotal Phase 3 registration study** in breast cancer under FDA Fast Track Designation
 - Advanced metastatic breast cancer causes over **40,000 deaths per year** in the U.S.
- Up to 2-fold increase in survival vs. comparable patients in the literature
- Remarkable clinical efficacy data in patients with CNS (brain) metastases



WHAT WE DO:

- Express tumor antigens and GM-CSF to activate specific cancer fighting CD4+ and CD8+ T cells
- Directly stimulate the immune system to enhance targeted killing of cancer cells

HOW ARE PATIENTS RESPONDING?

Safety & efficacy data similar or superior to that of approved breast cancer drugs when used to treat similar (advanced stage) patients

- Phase 2 Bria-IMT metastatic breast cancer study**
- Overall survival (OS) of **13.4 months** in patients treated with phase 3 formulation (n=37) vs. 5.9-9.8 months* in similar metastatic breast cancer patients who have failed 2+ prior therapy attempts
- OS of **17.3 months** in patients treated with phase 3 formulation since 2022 (n=25)
- Similar responses seen in patients resistant to Antibody Drug Conjugates (ADCs) and Check Point Inhibitors (CPIs)
- Acceptable safety profile to date

REMARKABLE RESPONDERS HIGHLIGHTED

Baseline Scans

Six months
On Treatment Scans

- Patient failed 13 prior treatment regimens
- Tumor causing left eye proptosis (eye bulging) completely resolved

Pre-treatment

3 Months

6 Months

11 Months

- Patient failed 8 prior regimens including ADC Enhertu®
- 100% resolution of brain metastasis and improvement elsewhere

* Cortes J, et al. Annals of Oncology 2018; Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17; O'Shaughnessy J et al. Breast Cancer Res Treat. 2022; Tripathy D, et al. JAMA Oncol. 2022; Bardia A, et al. J Clin Oncol. 2024 May 20;42(15):1738-1744


WHAT DOES FDA THINK?



- Fast-Track designation granted
- Phase 2a directly into pivotal Phase 3 study
- Survival-related end points for pivotal study
- Single Phase 3 study for approval (no confirmatory study required)


HOW DO WE GET FDA APPROVAL?

- Analyze at 144 events (deaths)
 - If hazard ratio (HR) is ≤ 0.6 ... approved!
 - If > 0.6 , continue to completion with HR target of 0.7




WHAT'S NEXT?

- Bria-OTS™ (*off-the-shelf approach*) Phase 1/2a clinical trial enrolling
 - BriaCell immunotherapy is most effective in human leukocyte antigen (HLA) type matched patients
 - Bria-OTS expresses 15 unique HLA types, providing off the shelf matched treatment to >99% of patients
 - Simple saliva test delivers personalized Bria-OTS immunotherapy
 - Platform technology for breast, prostate, lung, melanoma



Results of first patient treated:

- Complete resolution of lung lesion at two months
- Stable disease elsewhere



Forward Looking Statements

BriaCell Therapeutics Corp. ("BriaCell")

This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of BriaCell Therapeutics Corp. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Company makes certain filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission (the "SEC"), all of which are available under our profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. For a more complete discussion of the risk factors affecting our business, please refer to these filings.

Our public communications, including this presentation, and SEDAR+ and SEC filings, may contain statements related to future, not past, events. These forward-looking statements are based upon current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as "believes," "estimates," "anticipates," "targets," "expects," "plans," "projects," "intends," "predicts," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

These forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our reliance on third parties to carry out a large portion of our business; the possibility that pre-clinical and initial clinical trials will not necessarily be predictive of future results; our ability to obtain additional capital to continue our operations; our reliance on key personnel; our success in completing the development of our products, commercializing our products or generating significant revenues; our ability to successfully develop, maintain and protect our proprietary products and technologies; and potential difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of visiting or traveling to our clinical trial sites because of the outbreak of COVID-19.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this presentation.